CT-P59

BIOLOGICAL3 trials

Sponsors

Celltrion

Conditions

SARS-CoV-2 Infection

Phase 1

To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects

CompletedNCT04525079

CelltrionSARS-CoV-2 Infection

Start: 2020-07-18End: 2020-11-05Updated: 2021-11-16

This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)

CompletedNCT04593641

CelltrionSARS-CoV-2 Infection

Start: 2020-09-04End: 2021-04-05Updated: 2022-04-08

Phase 2

A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection

CompletedNCT04602000

CelltrionSARS-CoV-2 Infection

Start: 2020-10-05End: 2021-10-20Updated: 2022-07-20

Related Papers

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019

Open Forum Infectious Diseases2022-08-0124 citations

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019

Open Forum Infectious Diseases2022-02-0242 citations

Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.

2021-08-2342 citations